@ukpdam she actually says 75% but IMO, she should have read 75 of 90 patients so 83% (see captions)
see 5.15 mark - thanks to @randomvirus and @dplane
May be leaked information?
83% would represent IMO, overwhelming efficacy I would have thought !
I’m looking forward to the 90 patient readout by the independent Data Safety Monitoring Board (DSMB) who will complete the first interim analysis of the Phase 3 trial of Remestemcel-L in ventilator dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) in early September!
@ukpdam she actually says 75% but IMO, she should have read 75...
-
- There are more pages in this discussion • 12,751 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |